Advertisement
Letter to the Editor| Volume 103, P122-125, September 2022

Download started.

Ok

Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma

  • Byungyoon Yun
    Affiliations
    Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Sang Hoon Ahn
    Affiliations
    Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun–gu, Seoul 03722, Republic of Korea

    Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea

    Yonsei Liver Centre, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
    Search for articles by this author
  • Juyeon Oh
    Affiliations
    Department of Public Health, Graduate School, Yonsei University College of Medicine, Seoul, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Jin-Ha Yoon
    Correspondence
    Corresponding author at: Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

    Department of Occupational Health, Department of Preventive Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun–gu, Seoul 03722, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Beom Kyung Kim
    Correspondence
    Corresponding author at: Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun–gu, Seoul 03722, Republic of Korea.
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun–gu, Seoul 03722, Republic of Korea

    Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea

    Yonsei Liver Centre, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
Published:July 11, 2022DOI:https://doi.org/10.1016/j.ejim.2022.07.003
Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma
Previous ArticleUltrasound assessment of splanchnic circulation in Systemic Sclerosis: a non-invasive approach for the study of bowel vasculopathy?
Next ArticleSerum cystatin C, cystatin C level change and risk of atrial fibrillation
      Potent antiviral therapy (AVT) against hepatitis B virus (HBV) can induce regression of liver fibrosis, thereby reducing the development of liver cirrhosis and hepatocellular carcinoma (HCC) [
      • Yim H.J.
      • Kim J.H.
      • Park J.Y.
      • Yoon E.L.
      • Park H.
      • Kwon J.H.
      • et al.
      Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop.
      Clin Mol Hepatol. 2020; 26: 411-429
      ]. A high recurrence rate even after curative surgical resection of HCC remains a major challenge [
      • Lee J.H.
      • Kim B.K.
      • Park S.Y.
      • Tak W.Y.
      • Park J.Y.
      • Kim D.Y.
      • et al.
      The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
      Eur J Intern Med. 2021; 89: 48-55
      ].

      Keywords

      Abbreviations:

      AVT (antiviral therapy), HBV (hepatitis B virus), HCC (hepatocellular carcinoma), ETV (entecavir), TDF (tenofovir disoproxil fumarate), NHIS (national health insurance service), PS (propensity score), IPTW (inverse probability treatment weighting), HR (hazard ratio), CI (confidence interval), CHB (chronic hepatitis B), HCV (hepatitis C virus), HIV (human immunodeficiency virus), LC (liver cirrhosis), ALD (alcoholic liver disease), TAF (tenofovir alafenamide), IFN (interferon)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Yim H.J.
        • Kim J.H.
        • Park J.Y.
        • Yoon E.L.
        • Park H.
        • Kwon J.H.
        • et al.
        Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop.
        Clin Mol Hepatol. 2020; 26: 411-429
        View in Article
        • Lee J.H.
        • Kim B.K.
        • Park S.Y.
        • Tak W.Y.
        • Park J.Y.
        • Kim D.Y.
        • et al.
        The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
        Eur J Intern Med. 2021; 89: 48-55
        View in Article
        • Lee S.W.
        • Choi J.
        • Kim S.U.
        • Lim Y.S.
        Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma.
        Clin Mol Hepatol. 2021; 27: 402-412
        View in Article
        • van Erpecum K.J.
        • Sonneveld M.J.
        Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: is tenofovir or entecavir preferred?.
        Eur J Intern Med. 2021; 89: 27-29
        View in Article
        • Choi J.
        • Jo C.
        • Lim Y.S.
        Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
        Hepatology. 2021; 73: 661-673
        View in Article
        • Wang X.H.
        • Hu Z.L.
        • Fu Y.Z.
        • Hou J.Y.
        • Li W.X.
        • Zhang Y.J.
        • et al.
        Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
        J Gastroenterol. 2022; 57: 185-198
        View in Article
        • Tsai M.C.
        • Wang C.C.
        • Lee W.C.
        • Lin C.C.
        • Chang K.C.
        • Chen C.H.
        • et al.
        Tenofovir is superior to entecavir on tertiary prevention for BCLC stage 0/A hepatocellular carcinoma after curative resection.
        Liver Cancer. 2022; 11: 22-37
        View in Article
        • de Groen R.A.
        • McPhee F.
        • Friborg J.
        • Janssen H.L.
        • Boonstra A.
        Endogenous IFNlambda in viral hepatitis patients.
        J Interf Cytokine Res. 2014; 34: 552-556
        View in Article
        • Bruno S.
        • Thompson A.J.
        • Critelli R.
        • Crosignani A.
        • Rossi S.
        • De Lisi S.
        • et al.
        Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study.
        Antivir Res. 2015; 113: 27-32
        View in Article
        • Korean Association for the Study of the Liver (KASL)
        KASL clinical practice guidelines for management of chronic hepatitis B.
        Clin Mol Hepatol. 2019; 25: 93-159
        View in Article

      Article info

      Publication history

      Published online: July 11, 2022
      Accepted: July 5, 2022
      Received: June 28, 2022

      Identification

      DOI: https://doi.org/10.1016/j.ejim.2022.07.003

      Copyright

      © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX